Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia

doi:10.3390/ijms22147310

CNU IR > Pharmacy and Science > Dept. of Biotechnology (including master's program) > Periodical Articles > Item 310902800/34397

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34397

Title:	Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
Authors:	Chen, Pei-Yi Gao, Wan-Yun Liou, Je-Wen Lin, Ching-Yen Wu, Ming-Jiuan Yen, Jui-Hung
Contributors:	Buddhist Tzu Chi Med Fdn, Hualien Tzu Chi Hosp, Ctr Med Genet Tzu Chi Univ, Dept Mol Biol & Human Genet Tzu Chi Univ, Inst Med Sci Tzu Chi Univ, Sch Med, Dept Biochem Chia Nan Univ Pharm & Sci, Dept Biotechnol
Keywords:	dyslipidemia TG-rich lipoproteins ASCVDs ANGPTL3 lipoprotein lipase
Date:	2021
Issue Date:	2023-11-11 11:49:34 (UTC+8)
Publisher:	MDPI
Abstract:	Dyslipidemia is characterized by increasing plasma levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TGs) and TG-rich lipoproteins (TGRLs) and is a major risk factor for the development of atherosclerotic cardiovascular disorders (ASCVDs). It is important to understand the metabolic mechanisms underlying dyslipidemia to develop effective strategies against ASCVDs. Angiopoietin-like 3 (ANGPTL3), a member of the angiopoietin-like protein family exclusively synthesized in the liver, has been demonstrated to be a critical regulator of lipoprotein metabolism to inhibit lipoprotein lipase (LPL) activity. Genetic, biochemical, and clinical studies in animals and humans have shown that loss of function, inactivation, or downregulated expression of ANGPTL3 is associated with an obvious reduction in plasma levels of TGs, LDL-C, and high-density lipoprotein-cholesterol (HDL-C), atherosclerotic lesions, and the risk of cardiovascular events. Therefore, ANGPTL3 is considered an alternative target for lipid-lowering therapy. Emerging studies have focused on ANGPTL3 inhibition via antisense oligonucleotides (ASOs) and monoclonal antibody-based therapies, which have been carried out in mouse or monkey models and in human clinical studies for the management of dyslipidemia and ASCVDs. This review will summarize the current literature on the important role of ANGPTL3 in controlling lipoprotein metabolism and dyslipidemia, with an emphasis on anti-ANGPTL3 therapies as a potential strategy for the treatment of dyslipidemia and ASCVDs.
Relation:	INT J MOL SCI, v.22, n.14
Appears in Collections:	[Dept. of Biotechnology (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
ijms-22-07310.pdf		1590Kb	Adobe PDF	65	View/Open
index.html		0Kb	HTML	153	View/Open

Loading...